|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new... |
|
|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in hematology and hematology-oncology. Other members of the care team may also participate.
Program Overview
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing ... |
|
|
WEBINAR: Metronomic Chemotherapy: Hope vs. Hype
Metronomic chemotherapy has become quite popular with oncologists and general practitioners. There are some basic scientific data addressing its mechanism of action, however, the vast amount of data is purely retrospective in nature. These studies vary in drug dosage and protocols used making assessment between studies challenging. On top of this, there are no good surrogate markers for efficacy to help guide clinicians. Last, the use of metronomic therapy has opened our eyes to the challenges... |
|